| |
著者: L A Drake, N H Shear, J P Arlette, R Cloutier, F W Danby, B E Elewski, S Garnis-Jones, J M Giroux, D Gratton, W Gulliver, P Hull, H E Jones, M Journet, A L Krol, J J Leyden, S C Maddin, J B Ross, R C Savin, R K Scher, G R Sibbald, N H Tawfik, N Zaias, M Tolpin, S Evans, J E Birnbaum
雑誌名: J Am Acad Dermatol. 1997 Nov;37(5 Pt 1):740-5.
Abstract/Text
BACKGROUND: Onychomycosis is an increasing problem with limited therapeutic options.
OBJECTIVE: We evaluated the safety and efficacy, of oral terbinafine, a new fungicidal antimycotic, in patients with toenail onychomycosis.
METHODS: A North American multicenter, double-blind, placebo-controlled study evaluated the mycologic and clinical efficacy of oral terbinafine 250 mg/day for 12 or 24 weeks in 358 patients with toenail onychomycosis.
RESULTS: A total of 74% of patients treated with 12 or 24 weeks of terbinafine achieved a successful clinical outcome. Approximately 11% of terbinafine responders showed evidence of relapse 18 of 21 months after cessation of treatment. Terbinafine was well tolerated; most adverse events were transient and mild to moderate in severity.
CONCLUSION: The results of this study confirm that oral terbinafine is a safe and effective therapy for the treatment of onychomycosis.
PMID 9366820 J Am Acad Dermatol. 1997 Nov;37(5 Pt 1):740-5.
|
